Markets:

Overview

News

Currencies

International

Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

14.75 -0.05 (-0.34%)

Streaming Delayed Price Updated: 2:00 PM EDT, Mar 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis

April 19, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Aurinia Pharmaceuticals Inc. (AUPH)

April 19, 2022

From Robbins LLP

Via Business Wire

EQUITY ALERT: Rosen Law Firm Encourages Aurinia Pharmaceuticals Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – AUPH

April 18, 2022

From The Rosen Law Firm, P.A.

Via Business Wire

Why Aurinia Pharmaceuticals Tumbled Despite Its 'Aggressive' 2022 Outlook ↗

February 28, 2022

The company expects 150%-200% growth in its key product. But that wasn't enough.

Via Investor's Business Daily

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

AURINIA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Aurinia Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

April 15, 2022

From Bragar Eagel & Squire, P.C.

Via Business Wire

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Investor Notice: Investigation over Possible Violations of Securities Laws ↗

April 15, 2022

San Diego, CA -- (SBWIRE) -- 04/15/2022 -- An investigation was announced over potential securities laws violations by Aurinia Pharmaceuticals Inc. in connection with certain financial statements.

Via SBWire

AUPH INVESTOR ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation – AUPH

April 05, 2022

From Rosen Law Firm

Via Business Wire

Cramer Shares His Thoughts On PubMatic, Aurinia Pharmaceuticals And More ↗

April 05, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said although Kulicke and Soffa Industries, Inc.

Via Benzinga

Expert Ratings For Aurinia Pharmaceuticals ↗

December 10, 2021

Within the last quarter, Aurinia Pharmaceuticals (NASDAQ:AUPH) has observed...

Via Benzinga

Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings

April 04, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

March 16, 2022

From The Schall Law Firm

Via Business Wire

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Aurinia Pharmaceuticals Inc. with Losses of $100,000 to Contact the Firm

March 15, 2022

From The Schall Law Firm

Via Business Wire

AUPH INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation AUPH

March 11, 2022

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

What 4 Analyst Ratings Have To Say About Aurinia Pharmaceuticals ↗

March 08, 2022

Over the past 3 months, 4 analysts have published their opinion on Aurinia Pharmaceuticals (NASDAQ:AUPH) stock. These analysts are typically employed by large Wall Street banks...

Via Benzinga

10 Biggest Price Target Changes For Tuesday ↗

March 08, 2022

Raymond James cut the price target on Ciena Corporation (NYSE: CIEN) from $80 to $75. Ciena shares fell 10.9% to close at $58.76 on Monday. Telsey Advisory Group cut Capri...

Via Benzinga

42 Stocks Moving In Monday's Mid-Day Session ↗

February 28, 2022

Gainers Mullen Automotive, Inc. (NASDAQ: MULN) jumped 74.4% to $1.20 after the company reported progress on solid-state polymer battery pack development. Renewable Energy Group...

Via Benzinga

67 Biggest Movers From Yesterday ↗

March 01, 2022

Gainers Mullen Automotive, Inc. (NASDAQ: MULN) climbed 145.6% to close at $1.69 on Monday after the company reported progress on solid-state polymer battery pack...

Via Benzinga

Stocks Mixed as Investors Weigh Sanctions ↗

February 28, 2022

U.S. markets have cut a great deal of this morning's losses, though the Dow Jones Industrial Average (DJI) is still down

Via Talk Markets

Why Aurinia Pharmaceuticals Shares Are Falling Today ↗

February 28, 2022

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) is trading significantly lower Monday after the company reported declining fourth-quarter financial results on a year-over-year basis....

Via Benzinga

Mid-Morning Market Update: Markets Open Lower Amid Ongoing Russia-Ukraine Conflict ↗

February 28, 2022

U.S. stocks opened on a downbeat note this morning, amid the ongoing Russia-Ukraine conflict, which has led to increased US sanctions on Russia. Following the market opening...

Via Benzinga

Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates

February 28, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals to Release Fourth Quarter and Year End 2021 Financial Results on February 28, 2021

February 09, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference

February 03, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences

January 04, 2022

From Aurinia Pharmaceuticals Inc.

Via Business Wire

Aurinia's Voclosporin Shows favorable Risk/Benefit Profile Over 3 Years In Lupus Nephritis ↗

December 09, 2021

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has posted topline results from the AURORA 2 continuation study evaluating the long-term safety and tolerability of...

Via Benzinga

The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO ↗

December 09, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Committee Votes Against Recommending Approval Of Kidney Disease Drug...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 10, 2021 ↗

December 10, 2021

Upgrades According to JP Morgan, the prior rating for Arconic Corp (NYSE:

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

December 09, 2021

Good morning, trader! It's time to kick off another busy day of trading with the biggest pre-market stock movers for Thursday!

Via InvestorPlace

Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN)

December 09, 2021

From Aurinia Pharmaceuticals Inc.

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.